The blogs for pharma Diaries

As matters stand, the outlook for Alzheimer’s therapy is a little more auspicious. Especially, There have been a surge of pleasure – and an ensuing backwash of scepticism – pursuing the publication of complete outcomes from Clarity Advertisement, a Phase III confirmatory trial with Eisai and Biogen’s anti-amyloid mAb, lecanemab, in early Al

read more